ATE226831T1 - Impfstoff gegen mittelohrentzündung - Google Patents

Impfstoff gegen mittelohrentzündung

Info

Publication number
ATE226831T1
ATE226831T1 AT94922428T AT94922428T ATE226831T1 AT E226831 T1 ATE226831 T1 AT E226831T1 AT 94922428 T AT94922428 T AT 94922428T AT 94922428 T AT94922428 T AT 94922428T AT E226831 T1 ATE226831 T1 AT E226831T1
Authority
AT
Austria
Prior art keywords
fimbrin
vaccine against
ear inflammation
entire ear
against entire
Prior art date
Application number
AT94922428T
Other languages
English (en)
Inventor
Pappachan E Kolattukudy
Lauren O Bakaletz
Tatiana Sirakova
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of ATE226831T1 publication Critical patent/ATE226831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94922428T 1993-05-18 1994-05-12 Impfstoff gegen mittelohrentzündung ATE226831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6544293A 1993-05-18 1993-05-18
PCT/US1994/005477 WO1994026304A1 (en) 1993-05-18 1994-05-12 Otitis media vaccine

Publications (1)

Publication Number Publication Date
ATE226831T1 true ATE226831T1 (de) 2002-11-15

Family

ID=22062752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94922428T ATE226831T1 (de) 1993-05-18 1994-05-12 Impfstoff gegen mittelohrentzündung

Country Status (9)

Country Link
US (3) US5766608A (de)
EP (2) EP1300156A3 (de)
JP (1) JP3429313B2 (de)
AT (1) ATE226831T1 (de)
DE (1) DE69431624T2 (de)
DK (1) DK0699076T3 (de)
ES (1) ES2185658T3 (de)
PT (1) PT699076E (de)
WO (1) WO1994026304A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung
WO1994027435A1 (en) * 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
PT1129064E (pt) * 1998-11-12 2008-01-31 Invitrogen Corp Reagentes de transfecção
BR0009166A (pt) 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
ES2537737T3 (es) 2002-08-02 2015-06-11 Glaxosmithkline Biologicals S.A. Composiciones de vacuna que comprenden lipooligosacáridos de inmunotipo L2 y/o L3 de Neisseria meningitidis de IgtB
MXPA05004528A (es) 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
CA2539715C (en) 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US7811591B2 (en) * 2005-07-08 2010-10-12 Nationwide Children's Hospital, Inc. Chimeric vaccine for haemophilus influenzae-induced disease
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
ES2809167T3 (es) 2006-01-17 2021-03-03 Forsgren Arne Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE)
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
US9127306B2 (en) 2008-02-15 2015-09-08 Life Technologies Corporation Methods and apparatuses for nucleic acid shearing by sonication
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CA2792683A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Neisserial fhbp vaccine composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CA2838188C (en) 2011-06-04 2017-04-18 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
US9855326B2 (en) 2013-03-08 2018-01-02 Research Institute At Nationwide Children's Hospital Transcutaneous haemophilus influenzae vaccine formulations and methods
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗
US12551553B2 (en) 2018-11-29 2026-02-17 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
EP3980044A1 (de) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponinreinigung
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
EP4558170A1 (de) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Kontinuierliches verfahren zur herstellung von impfstoffen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5110908A (en) * 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung

Also Published As

Publication number Publication date
EP0699076B1 (de) 2002-10-30
US6562349B1 (en) 2003-05-13
EP0699076A1 (de) 1996-03-06
WO1994026304A1 (en) 1994-11-24
EP1300156A2 (de) 2003-04-09
US5766608A (en) 1998-06-16
US6030626A (en) 2000-02-29
EP0699076A4 (de) 1999-09-08
JP3429313B2 (ja) 2003-07-22
ES2185658T3 (es) 2003-05-01
DE69431624D1 (de) 2002-12-05
EP1300156A3 (de) 2003-05-07
JPH09500104A (ja) 1997-01-07
PT699076E (pt) 2003-03-31
DK0699076T3 (da) 2003-03-03
DE69431624T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE226831T1 (de) Impfstoff gegen mittelohrentzündung
NO953033L (no) Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse
MX9701025A (es) Genes de penicilina g acilasa mutados.
HUP9801638A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló proteáz K variánsok
CA2265976A1 (en) High level expression of proteins
DK0781329T3 (da) Overekspression af mammale og virale proteiner
FI943389L (fi) Bacillus-lajista saatu ksylanaasi, tällaisen ksylanaasin ja muiden proteiinien ekspressiovektori, niiden isäntäorganismit ja käyttö
DE69129604D1 (de) Mutierte beta-Lactamacylasegene
EP1967525A3 (de) Verfahren zur Regulierung der Immunfunktion in Primaten unter Verwendung des foxp3-Proteins
ATE64619T1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
AU3055495A (en) Recombinant mersacidin and a method for production
HUP9800767A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló szubtilizin DY variánsok
AU8258591A (en) Human mk gene and protein sequence
HUP9802069A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló termitáz variánsok
DK0769056T3 (da) Ikke-splejsende verianter af gp350/220
AU2002211446A1 (en) 32144, a human fatty acid amide hydrolase and uses thereof
EP1251176A3 (de) Expressionssysteme, die selbstspaltende Fusionsproteine verwenden sowie ein reduzierendes Polypeptid
AU9730798A (en) Epoxide hydrolase
WO2001044289A3 (en) Modified leukotoxin gene and protein
WO2004096833A3 (en) Inducers of recombinant protein expression
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
FI960951A0 (fi) Akarboosibiosynteesigeenejä Actinoplanes sp:stä, menetelmiä niiden eristämiseksi sekä niiden käyttö
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
WO2003008621A3 (en) 87144, human amino acid transporter family member and uses therefor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0699076

Country of ref document: EP

REN Ceased due to non-payment of the annual fee